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Background: Treatment of symmetrical onychomadesis (symmetrical lupoid onychodystrophy) is a challenging
task for dermatologists. The acute phase is characterized by sloughing of claw plates and loose claws have to be
removed and secondary infections treated. The goal of long-term treatment is to allow claws to re-grow with normal
quality and to achieve life-long lack of recurrence. The aim of this randomized treatment trial was to see if adding fish
oil or cyclosporine to a diet rich in omega-3 could improve the treatment outcome of symmetrical onychomadesis in
Gordon and English setters. All dogs were fed Eukanuba Veterinary Diets Dermatosis® exclusively during the six month
treatment trial. The treatment outcome was measured as the change in number of healthy claws during treatment, as
well as the long-term effect on hunting ability and recurrence of onychomadesis. The hypothesis was that cyclosporine
provides a stronger and different immune modulating property than fish oil and therefore would give a better treatment
outcome in dogs with symmetrical onychomadesis eating a diet rich in omega-3 fatty acids.
Results: Six Gordon setters and one English setter were treated with 5 mg/kg cyclosporine once daily for six months
and seven Gordon setters were treated with 10 ml Dr Baddaky fish oil® once daily for six months. All dogs were
evaluated every month and the numbers of healthy claws were recorded.
There was a statistically significant improvement in the number of healthy claws after six months of treatment with a
median increase of 13.5 claws for both groups. However, there was no statistically significant difference between the
two treatment groups regarding the improvement in number of healthy claws, as assessed using the Wilcoxon rank-sum
test (P = 0.15). Dogs in the cyclosporine group had a median increase of 10 healthy claws after six months of treatment
while the median for the fish oil group was 14. Long-term cure was not achieved with either treatment.
Conclusion: Cyclosporine and fish oil appeared to be equally effective in treating symmetrical onychomadesis when the
dog is fed a diet high in omega-3.
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Dogs often damage their claws during hunting, but with
symmetrical onychomadesis all claws slough off within
three months and when the claws grow back, they are
brittle and misshapen (onychodystrophy). The dogs ex-
perience pain in the acute phase of the disease. Symmet-
rical onychomadesis also diminishes the dogs’ hunting
abilities and welfare through the lack of functional claws
[1]. Previously, symmetrical onychomadesis was named
canine symmetrical lupoid onychodystrophy (SLO) and
was first described by Scott et al. [2]. The disease
was reported to affect different breeds of dogs and
mainly dogs between three and eight years of age.
According to Scott et al. [2], affected dogs shed their
claws (onychomadesis) without any signs of systemic
disease and the claws are dystrophic when they grow
back. Histopathological examinations of claw biopsies
showed band-like subepidermal infiltrates predomin-
antly along the dorsal aspect of the claw [2]. The dis-
ease is thought to be quite rare in most breeds, but
Ziener et al. [1] described a high prevalence among
Gordon and English setters in Norway.
Symmetrical onychomadesis is a difficult disease to
treat for a veterinary dermatologist. The re-growth of
claws and improvement takes time and is hard to moni-
tor accurately. Removal of damaged claw plates during
anaesthesia and treatment of secondary bacterial infec-
tions are essential in the acute phase of the disease. The
goal of the long-term treatment is to encourage re-
growth of normal quality claws and to prevent recur-
rence of onychomadesis. From a dermatological point of
view, a dog is cured of the disease if it develops new
claws of normal quality with no recurrence of onycho-
madesis during that dog’s lifetime. However, a significant
proportion of owners will report the dog as “cured” as
long as the dog does not have painful relapses of ony-
chomadesis, even though it still has onychodystrophy.
Traditionally, different immune-modulating drugs have
been used to treat dogs diagnosed with symmetrical
onychomadesis and complete or partial remission has
been achieved. Bergvall [3] demonstrated positive ef-
fects of omega-3 and omega-6 supplementation and other
treatment plans have included the use of tetracycline/
niacinamide, prednisolone, pentoxifylline and azathio-
prine [1-5]. Amputation of claws has also been used to
treat symmetrical onycomadesis with good results, but
this might be considered an overly aggressive treatment
option [6]. In addition, a pilot study using cyclosporine
in three dogs was conducted prior to initiating the
current treatment trial. All dogs had re-growth of normal
claws after treatment with cyclosporine for six months
(unpublished data).
The aim of this randomized treatment trial was to
compare fish oil supplementation and cyclosporine forthe treatment of symmetrical onychomadesis in Gordon
and English setters fed a diet rich in omega-3. The
effect of treatment was measured by comparing the
number of healthy claws in each dog before and after
six months of treatment and a follow-up survey was
done four years after the first dog was included in
the study. The hypothesis was that dogs fed a diet
rich in omega-3 would have a better treatment out-
come by adding cyclosporine than fish oil, given the
more pronounced and different immune modulating
properties of cyclosporine compared to fish oil. To
our knowledge this is the first randomized treatment
trial comparing different treatment regimens in sym-
metrical onychomadesis.
Materials and methods
Study population and design
Twelve Gordon setters and one English setter diagnosed
with symmetrical onychomadesis were recruited for a
treatment trial at the first author’s clinic in Norway from
2008 until 2010. Participation was based on informed
owner consent. The execution of the project was in
compliance with ethical regulations at the Norwegian
University of Life Sciences. All dogs were fed Eukanuba
Veterinary Diets (EVD) Dermatosis® exclusively from the
time of initiation of treatment and for the following
six months. In addition, the owners were allowed to
give their dogs’ potatoes and low fat white fish, as
these were ingredients in the diet, but nothing else.
EVD Dermatosis® was fed as an elimination diet dur-
ing the study because neither of the owners had previ-
ously given their dog catfish or herring, which are the
protein sources in EVD Dermatosis®.
Allocation to treatment groups was based on a system-
atic random procedure. This means that the first dog
was allocated to treatment group based on the toss of
a coin and subsequently every other dog entering the
study received either fish oil (Dr Baddaky fish oil®,
Dr. Baddaky AS, Skotterud, Norway) or cyclosporine
(Atopica®, Novartis, Oslo, Norway) to produce groups
of equal size. In both groups, the treatment was adminis-
tered per os by the owners. For practical reasons, the
treatment allocation was not blinded to the owner or to
the responsible veterinarian.
A thorough clinical and dermatological examination of
all dogs included in the study was performed. A medical
history was obtained with special emphasis on ruling out
previous skin diseases as a possible cause for the sym-
metrical onycomadesis. The number of claws without
visible signs of disease was recorded.
All dogs were placed under short time general anaes-
thesia to remove affected claw plates and inspect claw
beds at initial presentation. Samples for bacterial culture
and antimicrobial sensitivity were obtained from the
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study. Bacterial culture and sensitivity testing are rec-
ommended as a part of the diagnostic workup for dogs
with symmetrical onychomadesis [7]. All dogs had rou-
tine serum biochemistry and complete blood counts
performed. A thyroid gland profile including thyroid
stimulating hormone (TSH), total thyroxin (TT4), free
thyroxin (FT4) and cholesterol was also obtained from
all dogs.
The dogs received carprofen 2 mg/kg BID for five days
and amoxicillin clavulanic acid 10 mg/kg BID for four-
teen days following the removal of claw plates. Addition-
ally, the owners were instructed to use socks on the
dog’s paws as long as the claw beds were sore and to
wash the paws with antibacterial shampoo daily if exud-
ate was present.
The diagnosis was based on clinical signs of symmet-
rical onychomadesis on several claws (Figure 1A and B)
and by exclusion of other dermatological diseases as the
cause of onychomadesis. Only English and Gordon set-
ters with symmetrical onychomadesis on several claws
were included in the study. All dogs which had previ-
ously received any form of immune suppressive therapy
and all dogs showing only single digit onychomadesis
where excluded from this study.Figure 1 Onychomadesis in Gordon setter. A) Claw before treatment (o
claw after treatment; D) Onychodystrophy after treatment. Figures A and B
cyclosporine group; Figure D: dog no.7 in the fish oil group.Follow up
All dogs included in this study were presented for clinical
evaluation once monthly for six months. During these ex-
aminations, all claw beds were inspected and the absence
or presence of re-growth of claw plates was recorded.
Photo documentation of re-grown claws was performed.
Each claw was either characterized as normal (Figure 1C)
or as having signs of onychodystrophy (Figure 1D). For
every visit the number of claws that had become normal
was recorded. The outcome of the treatment trial was the
difference between the number of normal claws for each
individual at presentation and after six months of treat-
ment. After six months the medication was discontinued
and feeding of the dog’s original diet resumed. In 2012,
four years after the first dog was included in the study, a
follow-up questionnaire was mailed to the owners. The
owners were asked to describe their dog’s claws as normal,
misshapen (dystrophic) or with recurrence of onychomad-
esis. The dog’s hunting abilities after onychomadesis was
recorded. Furthermore, if the dog was not alive, the reason
for death/euthanasia was recorded.
Statistical methods
The change in number of healthy claws at presentation
and after six months of treatment was compared usingnychomadesis); B) Claw bed after removal of horn layer; C) Normal
: dog no. 3 in the cyclosporine group; Figure C: dog no. 5 in
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thermore, the effect of treatment in the two groups was
compared and the same test was also used to evaluate if
the sex of the dog influenced the treatment outcome.
The software package Stata/SE version 11 (Statacorp,
College Station, Texas) was used for the analysis. The
cut-off for statistical significance was set to P < 0.05. A
post-hoc power calculation was performed using JavaStat
(http://statpages.org/postpowr.html).
Results
Twelve Gordon and one English setter diagnosed with
symmetrical onychomadesis were included in the treat-
ment trial. The dogs were aged between three and seven
years when entering the study and this was their first
appearance of onychomadesis. The sex, age and weight
distributions, as well as the long-term outcome for dogs
in the two treatment groups are presented in Tables 1
and 2.
Dog no. 3 in the cyclosporine group is the same dog
as dog no. 7 in the fish oil group. This dog had normal
claws for six months after finishing treatment with
cyclosporine, before it relapsed with symmetrical ony-
chomadesis on all claws. The dog then entered the fish
oil supplementation group following random allocation.
A skin biopsy was performed in dog no. 6 from the
fish oil group because of mild alopecia when included
in the study. The histopathology report showed mild
atrophic dermatopathy and mild superficial perivascular
dermatitis. In general, the dogs showed only minor
changes in albumin, globulin, alanine transferase (ALT),
alkaline phosphatase (ALKP) and glucose. These were
considered clinically irrelevant.
Dog no. 7 in the cyclosporine group was diagnosed with
hypothyroidism when it was included in the study, based
on low serum TT4, FT4, high TSH and cholesterol values.
In this dog, a euthyroid state was maintained adequately byTable 1 Demographic data from seven dogs diagnosed with o














1 Male 3 23 6/18 18/18 Eu
2 Female 6 20 0/18 18/18 2
3 Female 4 18 5/18 15/18 1
4# Female 6 24 10/16 7/16 2
5 Female 3 19 0/18 6/18 3
6* Female 5 19 0/18 15/18 2
7 Male 7 23 10/18 17/18 2
Average 5 21 5/18 (median) 15/18 (median) 2
#Dog number four had two digits amputated.
*Dog number six was an English setter.supplementation of levothyroxine (Levaxin®, Nycomed
Pharma, Oslo, Norway). Dog no. 4 in the cyclosporine
group had values of TT4 of 52 nmmol/l (16–46 nmmol/l)
and tested thyroglobulin autoantibodies (TgAA) negative.
Dog no. 6 in the fish oil group had TT4 of 47 nmmol/l
(16–46) and she was not tested for TgAA.
All dogs had paronychia associated with onychomad-
esis. Bacterial culture and antimicrobial sensitivity ana-
lysis was obtained in nine dogs; the remaining dogs were
already on antibacterial treatment upon entering the
study. The results showed three samples with beta toxin
producing Staphylococcus sp. and one with S. pseudin-
termedius from the dogs in the cyclosporine group.
From dogs in the fish oil group, there were two samples
with a mixed culture of Gram positive and Gram nega-
tive bacteria and one sample with Streptococcus canis.
Adverse effects of cyclosporine and fish oil
None of the owners of dogs in the fish oil group re-
ported adverse effects of the treatment. In the cyclospor-
ine group, three owners reported that their dogs were
vomiting during the initial week of treatment, but this
resolved within the following four to five days, during
which a small amount of food was given with the drug.
Outcome
All dogs, except one in the cyclosporine group, showed
an improvement in the number of normal claws during
the course of the study period. The median number of
normal claws when entering the study was 5/18 for the
cyclosporine group and 0/18 for the fish oil group.
After six months, the median numbers of normal claws
where 15/18 in cyclosporine group and 14/18 in fish oil
group (Tables 1 and 2). There was a statistically signifi-
cant improvement in the number of healthy claws after
six months of treatment with a median increase of 13.5
claws for both groups. However, there was no statisticallynychomadesis allocated to cyclosporine treatment
ng term outcome; Claw outcome;
= Still episodes of onychomadesis
=Onychodystrophy with out





Is the dog used as a
hunting dog?








Table 2 Demographic data from seven Gordon setters diagnosed with onychomadesis allocated to fish oil treatment






nails after six months
of treatment
Long term outcome; Claw








Is the dog used as a
hunting dog?
1 Female 6 21 0/18 14/18 1 4 Yes
2 Male 6 22 0/18 16/18 1 4 Yes
3 Female 4 17 0/18 13/18 1 4 Yes
4 Male 7 19 4/18 18/16 1 4 Yes
5 Male 3 20 0/18 12/18 1 3 Yes
6 Female 7 15 0/18 14/18 2 3 No
7 Female 7 19 10/18 14/18 2 2 No
Average 6 19 0/18 (median) 14/18 (median) 1 (median) 3.4 (median4)
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the differences in number of healthy claws after six months
of treatment as assessed using the Wilcoxon rank-sum test
(P = 0.15). Furthermore, the change in number of healthy
claws over time did not differ by sex (P = 0.89). A post-hoc
power calculation showed that the power of this study to
detect a difference in number of healthy claws of four be-
tween the fish-oil and cyclosporine groups was 30%. By
doubling the sample size the observed difference could be
detected with a power of 80% and a P of 0.05.
None of the owners reported any recurrence of sym-
metrical onychomadesis in the first month after their
dog discontinued treatment and where fed their original
diet.
Four years after the first dog was included in the study
a questionnaire was mailed to the owners. In the cyclo-
sporine group; one dog had been euthanized due to
onychomadesis and aggressive behavior, one dog had
normal claws, one still had recurrence of onychomadesis
and four dogs had onychodystrophy. Four of the seven
dogs were used for hunting (Table 1).
In the fish oil group; two dogs had onychodystrophy
and five dogs had recurrence of onychomadesis. Five of
the seven dogs were used for hunting (Table 2).
None of the dogs, in either group, had received any
further treatment for their claw disease after completing
the trial.
Discussion
The primary aim of this randomized treatment trial was
to evaluate if adding cyclosporine to a diet rich in
omega-3 could improve treatment outcome regarding
canine symmetrical onychomadesis compared to adding
fish oil to the same diet. A second aim was to observe
the course of the disease on a long term basis after with-
drawal of treatment.
Evaluating the outcome in a prospective treatment
study of symmetrical onychomadesis is challenging,because within the same dog, claws will show different
stages of disease at any given time. If the inclusion criteria
of this treatment trial had been absence of normal claws,
the groups would have been more comparable at the start
and hence the results easier to interpret.
Therefore, in order to minimize the possible effect of
any difference between groups at inclusion into this
study, the change in number of normal claws was used
to assess treatment success. No difference in the change
of number of normal claws was detected between the
two groups. This could be due to low effect of adding
cyclosporine to a diet high in omega-3 when treating
symmetrical onychomadesis.
It was considered necessary to have a treatment period
of six months for studying a disease with such a long re-
covery phase. The results could potentially have been
different if the treatment period had been longer or
shorter than six months, but earlier studies have re-
ported efficacy of treatment within a time period of
three to four months [4].
To assess the natural course of the disease without
treatment, a follow up was done four years after the first
dog was included in the study. Owners reported that
even though none of the dogs were on any treatment, it
seemed that the dogs with recurrence of onychomadesis
or onychodystrophy showed less sign of pain and lame-
ness compared to what was seen during the initial acute
phase of the disease. In previous studies, effect of treat-
ment has been reported as excellent, good, partial or
poor, based on owner interviews [4]. Many owners and
their dogs will consider a good response to treatment to
be absence of painful relapses of onychomadesis, despite
the claws showing signs of onychodystrophy. In medical
terms a dog with symmetrical onychomadesis should be
classified as “cured” if it has no recurrence of sloughing
of claws for the remainder of its life, as well as complete
re-growth of normal claws. In this study only one dog in
the cyclosporine group was still “cured” after four years.
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higher if the dogs were kept on life- long treatment, but
the question is if the dogs need this, if they only have
onychodystrophy without pain and lameness. Perhaps a
diet change to a diet rich in omega-3 might be enough
as a long term treatment in the majority of cases, as long
as the affected claws are removed in the acute phase of
the disease. The results could also have been different in
heavier breeds known to be predisposed to symmetrical
onychomadesis such as Rhodesian ridgeback and giant
schnauzers. These breeds might possibly need life-long
treatment because they have a higher body weight
than setters and therefore could show more pain upon
recurrence.
Because Mueller et al. [5,7] showed that symmetrical
onychomadesis could be due to food allergy in two
cases, all the dogs in this trial where fed the same diet.
To rule out food responsive symmetrical onychomadesis
all the dogs were fed their original diet after completion
of the trial, and none of the owners reported any recur-
rence of symmetrical onychomadesis within the first
month. It was also important to assure that all dogs par-
ticipating in the study got the same amount of eicosa-
pentaenoic acid (EPA) and docosapentaenoic acid (DHA)
from the diet. A dose of EPA/DHA at 50–250 mg/kg body
weight appears to have an anti-inflammatory effect [8].
The mean weight of the dogs participating in the study
was 20 kg and a total dose of 1–5 g EPA/DHA daily would
therefore be sufficient to anticipate a treatment effect. In
this study each dog had a daily intake of 3.3 g EPA/DHA
from the diet. Every dog ate an average of 300 g food and
in EVD Dermatosis® the EPA level is 0.9% per gram and
the DPA level is 0.2% per gram.
In the fish oil group each dog had a daily intake of
2.7 g EPA/DHA from the fish oil supplementation.
Dr Baddaky fish oil® contains 165 mg EPA/ml, 106 mg
DHA/ml and 1.0 mg vitamin E/ml and each dog in the fish
oil group received 10 ml daily for six months.
Omega-3 fatty acids, in the form of fish oil, have previ-
ously been shown to have a good effect against symmet-
rical onychomadesis and are relatively inexpensive with
few side effects [5]. It is reported that neutrophils and
macrophages obtain a higher concentration of EPA and
DHA in cell membranes when dogs are fed fish oil. This
might contribute to modulating the immune response so
that less potent inflammatory mediators are produced.
Furthermore, the expression of MHC class I and II on
cell surfaces decreases in animals fed a diet rich in
omega-3 fatty acids [8-11].
Cyclosporine was chosen as a therapeutic agent for
comparison in this study because it had shown good re-
sponse in the pilot study and has previously been used
to treat canine immune mediated diseases such as atopic
dermatitis and anal furunculosis [12,13]. Cyclosporineis a potent immune suppressive agent that has been
shown to inhibit the activation of most cells involved
in cell-mediated immunity. The compound does not have
major impact on humoral immune response in the short
term.
Two dogs in the cyclosporine group and one dog in
the fish oil group had complete re-growth of normal
claws after six months of treatment. Twelve of the thir-
teen dogs had a higher number of normal claws at the
end of the treatment period. To which extent the
omega-3 from the EVD® diet contributed to the outcome
of this treatment trial is unknown, because a negative
control group that did not got the diet was not included
in the study design.
Potential selection bias of this study was avoided
through the random allocation of dogs to treatment
groups. There was no blinding of the treatment for the
veterinarian that performed the evaluation of the out-
come and this is a limitation of the study. Blinding was
not considered practically achievable because of the dif-
ferent formulation of the two drugs. The fact that a bi-
nominal scale was chosen to measure treatment effect
(number of affected claws before and after treatment) in-
stead of a graduated scale or subjective measurements of
improvement should decrease the risk for measurement
error introduced by the lack of blinding. The hypothesis
was that cyclosporine together with the diet would give
a better treatment outcome compared to fish oil with
diet, but after thirteen dogs, no significant difference be-
tween the two groups was observed. The post-hoc power
calculation showed that the power to detect a difference
in improvement in the magnitude of four claws between
the two treatment groups was 30%, and that a doubling
of the sample-size could have resulted in a power of 80%
for this difference and significance level. However, be-
cause a difference of this size was considered unlikely to
represent a biologically relevant effect the inclusion of
additional patients was stopped.
Conclusions
Cyclosporine and fish oil appeared to be equally effective
in treating symmetrical onychomadesis when the dog is
fed a diet high in omega-3. No statistically significant
differences in the change in number of healthy claws
were observed between dogs in the two treatment groups
after six months of treatment. Symmetrical onychomad-
esis has been described in several other breeds and it is
likely that the treatment regimens used in this trial could
be used for dogs from other breeds as well. With long
term follow-up, eleven of thirteen dogs continued to have
onychomadesis or onychodystrophy after discontinuation
of treatment and diet. However, the dogs appeared to live
well with their disease after discontinuing treatment,
although three dogs were not used for hunting because
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portant role in suppressing the inflammatory reaction
that takes place in the claw fold. Because of the high
costs and lack of effect of cyclosporine compared to fish
oil, we are inclined to suggest that omega-3 might be the
first choice of treatment for canine symmetrical onycho-
madesis incorporated in the diet or as a supplement.
However, the current study included a limited number of
dogs and further investigation is warranted before treat-
ment guidelines for the disease can be proposed.
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